INCB28060

{{Drugbox | Verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = N-[(1R)-1-(4-fluorophenyl)-2-[[4-(4-methylpiperazin-1-yl)anilino]carbonyl]ethyl]-4-(trifluoromethyl)benzamide | image = INCB28060_structure.png | width = 250 | alt = | tradename = | synonyms = Capmatinib | CAS_number = 1029712-80-8 | ATC_prefix = | ATC_suffix = | PubChem = 16005130 | ChemSpiderID = 13122113 | UNII = 7NFE54O27T | KEGG = D10850 | ChEMBL = 2103875 | C=23 | H=17 | F=4 | N=3 | O=1 | smiles = C1CN(CCN1)C2=CC=C(C=C2)NC(=O)C(C3=CC=C(C=C3)F)C(=O)NC4=CC=C(C=C4)C(F)(F)F }}

INCB28060, also known as Capmatinib, is a small molecule inhibitor of the c-Met receptor tyrosine kinase. It is primarily investigated for its potential use in the treatment of various types of cancer, particularly non-small cell lung cancer (NSCLC) with specific genetic mutations.

Mechanism of Action

INCB28060 functions by selectively inhibiting the activity of the c-Met receptor, which is a proto-oncogene that encodes a protein known as hepatocyte growth factor receptor (HGFR). The c-Met receptor is involved in various cellular processes, including proliferation, survival, and metastasis. Overexpression or mutation of c-Met has been implicated in the pathogenesis of several cancers. By inhibiting c-Met, INCB28060 can potentially reduce tumor growth and spread.

Clinical Development

INCB28060 has been evaluated in several clinical trials to assess its efficacy and safety in patients with advanced solid tumors, particularly those with alterations in the c-Met pathway. The drug has shown promise in treating patients with NSCLC harboring MET exon 14 skipping mutations, which are known to drive cancer progression.

Pharmacokinetics

The pharmacokinetic profile of INCB28060 includes its absorption, distribution, metabolism, and excretion characteristics. It is administered orally and has been shown to have a favorable bioavailability. The drug is metabolized primarily in the liver and excreted through both renal and fecal pathways.

Adverse Effects

Common adverse effects associated with INCB28060 include nausea, vomiting, fatigue, and peripheral edema. More serious side effects can include hepatotoxicity and interstitial lung disease, which require careful monitoring during treatment.

Regulatory Status

As of the latest updates, INCB28060 has received approval from regulatory agencies such as the U.S. Food and Drug Administration (FDA) for specific indications, particularly in the treatment of NSCLC with MET exon 14 skipping mutations.

Research and Future Directions

Ongoing research is focused on expanding the therapeutic applications of INCB28060 to other cancers with c-Met dysregulation. Combination therapies with other targeted agents or immunotherapies are also being explored to enhance its efficacy.

Also see

• c-Met receptor
• Non-small cell lung cancer
• Tyrosine kinase inhibitors
• Cancer treatment